Merck Reportedly Goes To Bat In Takeover Battle. Genomics Stock Flies.Investors Business Daily • 07/17/26
FDA signs off on Merck's cholesterol-lowering pill — the first oral treatment of its kindNew York Post • 07/16/26
The FDA approved Lipfendra, a first-of-its kind pill from Merck that is designed to help lower cholesterol levels beyond what statins alone can achieveWSJ • 07/16/26
Merck's LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with HypercholesterolemiaBusiness Wire • 07/16/26
Merck Says Blockbuster Keytruda Outperforms Chemotherapy in Advanced Endometrial CancerBenzinga • 07/15/26
Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026Business Wire • 07/15/26
FDA Expands MRK & PFE's Keytruda-Padcev Combo Use in Bladder CancerZacks Investment Research • 07/13/26
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)Business Wire • 07/10/26
MRK Surpasses 50- & 200-Day SMAs: Buy, Hold or Sell at Current Levels?Zacks Investment Research • 07/08/26
Merck (MRK) Stock Slides as Market Rises: Facts to Know Before You TradeZacks Investment Research • 07/06/26
Why MSTY Shareholders Are Facing Uncapped Losses Despite Weekly Distributions24/7 Wall Street • 07/05/26
Merck, AbbVie probed by US lawmakers over China clinical trials: reportProactive Investors • 06/30/26